These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38663101)

  • 1. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities.
    Yan S; Ji J; Zhang Z; Imam M; Chen H; Zhang D; Wang J
    Biomed Pharmacother; 2024 Jun; 175():116615. PubMed ID: 38663101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
    Suba Z
    Recent Pat Anticancer Drug Discov; 2018; 13(4):428-444. PubMed ID: 30027855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
    Osborne CK; Shou J; Massarweh S; Schiff R
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):865s-70s. PubMed ID: 15701879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
    Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
    PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
    Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
    Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
    Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
    Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
    Kulkoyluoglu E; Madak-Erdogan Z
    Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.
    Bowers LW; Cavazos DA; Maximo IX; Brenner AJ; Hursting SD; deGraffenried LA
    Breast Cancer Res; 2013; 15(4):R59. PubMed ID: 23880059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.
    Yoshimaru T; Komatsu M; Miyoshi Y; Honda J; Sasa M; Katagiri T
    Cancer Sci; 2015 May; 106(5):550-8. PubMed ID: 25736224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor signaling as a target for novel breast cancer therapeutics.
    Renoir JM; Marsaud V; Lazennec G
    Biochem Pharmacol; 2013 Feb; 85(4):449-65. PubMed ID: 23103568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
    Wu VS; Kanaya N; Lo C; Mortimer J; Chen S
    J Steroid Biochem Mol Biol; 2015 Sep; 153():45-53. PubMed ID: 25998416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells.
    Tsonis AI; Afratis N; Gialeli C; Ellina MI; Piperigkou Z; Skandalis SS; Theocharis AD; Tzanakakis GN; Karamanos NK
    FEBS J; 2013 May; 280(10):2248-59. PubMed ID: 23374155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors.
    Lu AS; Rouhimoghadam M; Arnatt CK; Filardo EJ; Salem AK
    Mol Pharm; 2021 Mar; 18(3):1455-1469. PubMed ID: 33600191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.